Arbutus Biopharma Corporation ABUS Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $191.45M+2,890% | $14.08M+128% | $14.61M+117% | $15.42M+53.2% | $6.4M-50.7% | ||
| $20.4M-57.1% | $25.24M-53.3% | $29.05M-53.7% | $37.54M-45.3% | $47.59M-32.8% | ||
| $15.95M-29.5% | $15.89M-28.1% | $16.92M-24.8% | $18.41M-22.7% | $22.63M+1.8% | ||
| —— | —— | —— | —— | —— | ||
| $12.8M-20.5% | $25.17M+577% | $24.97M+589% | $28.49M— | $16.09M— | ||
| $35M-60.7% | $52.24M-36.7% | $61.41M-31.7% | $75M-19.6% | $89.06M-4.3% | ||
| $35M-60.7% | $52.24M-36.7% | $61.41M-31.7% | $75M-19.6% | $89.06M-4.3% | ||
| $156.45M+289% | -$38.16M+50.0% | -$46.8M+43.7% | -$59.58M+28.4% | -$82.66M-3.3% | ||
| 81.7%+1,373pp | -271%+966pp | -320.4%+913pp | -386.5%+441pp | -1,290.9%-674pp | ||
| $86K-28.9% | $97K-29.2% | $109K-27.8% | $115K-31.5% | $121K-60.3% | ||
| $3.69M-40.9% | $4.07M-38.2% | $4.66M-29.3% | $5.45M-13.9% | $6.24M+4.6% | ||
| $4.27M-29.8% | $4.66M-27.2% | $4.53M-29.6% | $5.33M-13.5% | $6.08M+7.3% | ||
| $160.72M+310% | -$33.5M+52.1% | -$42.28M+44.9% | -$54.25M+29.6% | -$76.57M-2.9% | ||
| 84%+1,280pp | -237.9%+895pp | -289.4%+848pp | -351.9%+414pp | -1,195.9%-623pp | ||
| $0.83+302% | -$0.17+55.3% | -$0.23+46.5% | -$0.29+35.6% | -$0.41+6.8% | ||
| $0.84+305% | -$0.17+55.3% | -$0.23+46.5% | -$0.29+35.6% | -$0.41+6.8% | ||
| 771M+2.3% | 766.5M+3.8% | 760.5M+5.8% | 757.7M+8.7% | 753.4M+11.6% | ||
| 768.7M+2.0% | 765.6M+3.7% | 759.6M+5.7% | 756.9M+8.6% | 753.4M+11.6% | ||
| —— | —— | —— | —— | —— | ||
| —— | -$1.83M-170% | -$716.25K-136% | $397.5K-70.5% | $1.51M+113% | ||
| $160.69M+310% | -$33.46M+51.9% | -$42.32M+44.3% | -$54.13M+28.7% | -$76.37M-4.4% | ||
| —— | —— | —— | —— | —— | ||
| -$1K+96.9% | $14K+129% | -$20K-900% | -$3K-200% | -$32K-500% | ||
| $156.45M+289% | -$38.16M+50.0% | -$46.8M+43.7% | -$59.58M+28.4% | -$82.66M-3.3% | ||
| $156.57M+293% | -$37.72M+49.7% | -$46.11M+43.6% | -$58.56M+28.4% | -$81.29M-3.4% | ||
| $156.57M+293% | -$37.72M+49.7% | -$46.11M+43.6% | -$58.56M+28.4% | -$81.29M-3.4% | ||
| 81.8%+1,351pp | -267.8%+946pp | -315.7%+897pp | -379.9%+433pp | -1,269.5%-664pp | ||
| $156.45M+289% | -$38.16M+50.0% | -$46.8M+43.7% | -$59.58M+28.4% | -$82.66M-3.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Arbutus Biopharma Corporation's revenue?
- Arbutus Biopharma Corporation (ABUS) generated $191.4M in revenue over the trailing twelve months, up 2889.9% year over year.
- Is Arbutus Biopharma Corporation profitable?
- Arbutus Biopharma Corporation reported $160.7M in net income over the trailing twelve months, a 84.0% net margin.
- What is Arbutus Biopharma Corporation's earnings per share?
- Arbutus Biopharma Corporation's diluted EPS over the trailing twelve months is $0.83.
- Where does Arbutus Biopharma Corporation's income statement data come from?
- Every line is extracted from Arbutus Biopharma Corporation's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
